THE SEARLE COMPANY LIMITED

Searle Secures Pakistani Regulatory Approval for Denosumab Biosimilar Injections

- The Searle Company Limited has obtained registration from Pakistan's Drug Regulatory Authority for Denosumab biosimilar injections in 60mg and 120mg doses. - The company holds marketing and sales rights in Pakistan under a licensing agreement with Chinese manufacturer Mabwell Pharmaceuticals. - The 60mg formulation targets osteoporosis management while the 120mg dose is intended for oncology care applications. - Searle is preparing for commercial launch, marking a significant expansion of its product portfolio in Pakistan's pharmaceutical market.